Cargando…

Essential competencies for physical therapist managing individuals with spinal muscular atrophy: A delphi study

BACKGROUND AND PURPOSE: With the availability and development of disease-modifying therapies for individuals with spinal muscular atrophy (SMA), new emerging phenotypes must be characterized, and potential new treatment paradigms tested. There is an urgent demand to develop an educational program th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Timmerberg, Jean Fitzpatrick, Krosschell, Kristin J., Dunaway Young, Sally, Uher, David, Yun, Chris, Montes, Jacqueline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062020/ https://www.ncbi.nlm.nih.gov/pubmed/33886555 http://dx.doi.org/10.1371/journal.pone.0249279

Ejemplares similares

Measuring Fatigue and Fatigability in Spinal Muscular Atrophy (SMA): Challenges and Opportunities
por: Rodriguez-Torres, Rafael S., et al.
Publicado: (2023)

How is Physical Activity Measured in Spinal Muscular Atrophy and Duchenne Muscular Dystrophy?
por: Uher, David, et al.
Publicado: (2023)

Developmental milestones in type I spinal muscular atrophy
por: De Sanctis, Roberto, et al.
Publicado: (2016)

Diminished muscle oxygen uptake and fatigue in spinal muscular atrophy
por: Montes, Jacqueline, et al.
Publicado: (2021)

Nusinersen improves walking distance and reduces fatigue in later‐onset spinal muscular atrophy
por: Montes, Jacqueline, et al.
Publicado: (2019)

Single-Blind, Randomized, Controlled Clinical Trial of Exercise in Ambulatory Spinal Muscular Atrophy: Why are the Results Negative?
por: Montes, Jacqueline, et al.
Publicado: (2015)

Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy
por: Pera, Maria C., et al.
Publicado: (2017)

Nusinersen Treatment in Adults With Spinal Muscular Atrophy
por: Duong, Tina, et al.
Publicado: (2021)

Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor Function †
por: Dunaway Young, Sally, et al.
Publicado: (2023)

Ambulatory function in spinal muscular atrophy: Age-related patterns of progression
por: Montes, Jacqueline, et al.
Publicado: (2018)

Phase II Open Label Study of Valproic Acid in Spinal Muscular Atrophy
por: Swoboda, Kathryn J., et al.
Publicado: (2009)

Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
por: Pera, Maria Carmela, et al.
Publicado: (2021)

Cerebrospinal Fluid Proteomic Changes after Nusinersen in Patients with Spinal Muscular Atrophy
por: Beaudin, Marie, et al.
Publicado: (2023)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Different trajectories in upper limb and gross motor function in spinal muscular atrophy
por: Coratti, Giorgia, et al.
Publicado: (2021)

Assessing Bulbar Function in Spinal Muscular Atrophy Using Patient-Reported Outcomes
por: Dunaway Young, Sally, et al.
Publicado: (2023)

Mitochondrial abnormalities in spinal and bulbar muscular atrophy
por: Ranganathan, Srikanth, et al.
Publicado: (2009)

Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool
por: Ramsey, Danielle, et al.
Publicado: (2017)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Spinal Muscular Atrophy and Ependymoma
por: Albakr, Aishah, et al.
Publicado: (2017)

Risdiplam for spinal muscular atrophy
Publicado: (2022)

Modeling Spinal Muscular Atrophy in Drosophila
por: Chang, Howard Chia-Hao, et al.
Publicado: (2008)

Carrier screening for spinal muscular atrophy
por: Prior, Thomas W.
Publicado: (2008)

Androgens in spinal and bulbar muscular atrophy
Publicado: (2012)

Spinal Muscular Atrophy: The Treatment Approved
por: Tabet, Rabih, et al.
Publicado: (2017)

Advances in spinal muscular atrophy therapeutics
por: Parente, Valeria, et al.
Publicado: (2018)

Euglycemic Ketoacidosis in Spinal Muscular Atrophy
por: Stoimenis, Dimitrios, et al.
Publicado: (2019)

Metabolic Dysfunction in Spinal Muscular Atrophy
por: Deguise, Marc-Olivier, et al.
Publicado: (2021)

Update on Biomarkers in Spinal Muscular Atrophy
por: Pino, Megan G, et al.
Publicado: (2021)

Onasemnogene abeparvovec for spinal muscular atrophy
Publicado: (2022)

Mitochondrial Dysfunction in Spinal Muscular Atrophy
por: Zilio, Eleonora, et al.
Publicado: (2022)

Editorial: Advances in spinal muscular atrophy
por: Sun, Jianli
Publicado: (2023)

Erratum to: Patients with Spinal Muscular Atrophy Type 1 Achieve and Maintain Bulbar Function Following Onasemnogene Abeparvovec Treatment
por: McGrattan, Katlyn E., et al.
Publicado: (2023)

Patients with Spinal Muscular Atrophy Type 1 Achieve and Maintain Bulbar Function Following Onasemnogene Abeparvovec Treatment(1)
por: McGrattan, Katlyn E., et al.
Publicado: (2023)

Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study
por: Kolb, Stephen J., et al.
Publicado: (2016)

Importance and utilization frequency of essential competencies of Korean physical therapists
por: Choi, Junghyun, et al.
Publicado: (2020)

Identifying Biomarkers of Spinal Muscular Atrophy for Further Development
por: Glascock, Jacqueline, et al.
Publicado: (2023)

Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy
por: Lusakowska, Anna, et al.
Publicado: (2021)

Therapist competence, therapy quality, and therapist training
por: Fairburn, Christopher G., et al.
Publicado: (2011)

Longitudinal natural history of type I spinal muscular atrophy: a critical review
por: Mercuri, Eugenio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a0v3iq9t322b0kdtsma880ffbi